StemCo Biomedical Changes Name to Aldagen, Inc.
Name change reflects company's focus in regenerative medicine
Durham, NC – November 29, 2005 – StemCo Biomedical, Inc. today announced that it has changed its name to Aldagen, Inc. The change was made to reflect more accurately the company's focus and significant progress in the regenerative medicine field.
"Over the past year, our efforts have resulted in numerous preclinical, clinical and regulatory milestones, which will position Aldagen as the leading regenerative medicine company," said Ed Field, President of Aldagen. "We wanted to use a name that connects regenerative medicine to our proprietary adult stem cell isolation technology based on the expression of an enzyme, aldehyde dehydrogenase. We will make several public announcements over the next three months that will reflect our progress in initiating clinical studies and generating exciting preclinical data for various therapeutic applications in regenerative medicine."
"We are excited about the opportunity for Aldagen's products in the regenerative medicine field. They have the potential to address significant therapeutic markets where there is great unmet medical need," said Garheng Kong, Partner at Intersouth and board member of Aldagen.
About Aldagen, Inc.
Aldagen's proprietary products identify and isolate unique populations of adult stem cells with the potential to revolutionize treatments of cardiovascular disease and degenerative diseases. The Company is now testing these products in clinical trials.
To learn more about Aldagen's products for preparing optimal cell populations for adult stem cell therapy, the Company invites you to visit its website at www.aldagen.com.